Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Post by wildbird1on Mar 13, 2019 11:41am
140 Views
Post# 29478935

'' Once Burned, twice Shy''

'' Once Burned, twice Shy''We agree that J.Tripp in the past made some mistakes.The fact that he was alone in the decision making process, and his desire to bring these wonderfull tests to market faster, may have guided his decision making.

A new decision making process...

Today J.Tripp isn't alone anymore, he has two new big guy looking over his shoulder making sure he doesn't make bad moves.

-A new CCO(Chief Commercial Officer) David Byram, who came on board on July 12, 2018, and brought with him over 25 years of experience in his domain.

-And most of all (I love this guy) Dietrich Stephan who came on board August 15, 2018, he is a renowed Geneticist that know more about genenews tests than J.Tripp himself. He is also the ex CEO of LIFEX(make you wonder if he did quit his job as LIFEX CEO, just  to be able to fully concentrate on helping GEN), after all Dietrich Stephan did say (QUOTE) '' Genenews has developed the ''Holy-Grail of cancer tests'' (END of QUOTE).

A renowed Geneticist tha said ''Holy-Grail of cancer tests'' what else need to be said.

The fact of the matter is today, every new partnerships that Genenews will embark on, will be check and recheck many time by this new team, J.Tripp(CEO), D.Byram(CFO), and D.Stephan (LIFEX ex CEO).

This process take time, but it is worth waiting for.



Bullboard Posts